Patents by Inventor Nicholas G. Bacopoulos
Nicholas G. Bacopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100273732Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.Type: ApplicationFiled: July 2, 2010Publication date: October 28, 2010Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Paul A. Marks, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon, Richard A. Rifkind
-
Publication number: 20090012175Abstract: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: July 8, 2008Publication date: January 8, 2009Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Publication number: 20080249179Abstract: The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: October 30, 2007Publication date: October 9, 2008Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon, William Kevin Kelly
-
Publication number: 20080227862Abstract: The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: October 30, 2007Publication date: September 18, 2008Inventors: Victoria M. Richon, Judy H. Chiao, Thomas A. Miller, Nicholas G. Bacopoulos, Carolyn M. Paradise
-
Patent number: 7399787Abstract: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: GrantFiled: July 9, 2003Date of Patent: July 15, 2008Assignee: Merck HDAC Research, LLCInventors: Judy H. Chiao, Nicholas G. Bacopoulos, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Patent number: 7375137Abstract: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: GrantFiled: March 28, 2006Date of Patent: May 20, 2008Assignee: Merck HDAC Research, LLCInventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Patent number: 7148257Abstract: Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed.Type: GrantFiled: August 26, 2003Date of Patent: December 12, 2006Assignees: Merck HDAC Research, LLC, Sloan-Kettering Institute for Cancer ResearchInventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Publication number: 20040132825Abstract: The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: October 24, 2003Publication date: July 8, 2004Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Publication number: 20040127522Abstract: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: July 9, 2003Publication date: July 1, 2004Inventors: Judy H. Chiao, Nicholas G. Bacopoulos, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Publication number: 20040127523Abstract: The present invention relates to methods of treating cancers, e.g., lymphoma. More specifically, the present invention relates to methods of treating diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: September 16, 2003Publication date: July 1, 2004Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Publication number: 20040087631Abstract: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.Type: ApplicationFiled: August 26, 2003Publication date: May 6, 2004Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
-
Patent number: 5130338Abstract: A method of treating a chemical dependency in a mammal, comprising administering to a mammal in need of such treatment an amount of the compound (1S-cis)-4-(3, 4-dichlorophenyl)-1,2,3,4-tetraahydro-N-methyl-1-naphthalenamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in reducing or alleviating such dependency.Type: GrantFiled: February 28, 1991Date of Patent: July 14, 1992Assignee: Pfizer Inc.Inventors: Nicholas G. Bacopoulos, Peter A. Blick, B. Kenneth Koe, Evan R. Norris